New radiopharmaceutical heads to the FDA after Phase 3 win

Plus: Using oil, seed oils included, instead of butter lowered risk of premature death, says study

March 7, 2025 Check out STAT+

Sponsored By

Hey Cancer Briefing readers. Sharing that for a limited time only, you can get 50% off an annual STAT+ subscription. A pretty good deal if you ask me. Anyway, thanks for reading and hope you are taking care. —Alexa Lee, newsletter strategist

Scott Olson/Getty Images Using oil, seed oils included, instead of butter lowered risk of premature death, says study Despite concern about "seed oils," a study in JAMA Internal Medicine makes a case for oils like canola, along with olive oil, over butter. By Sarah Todd STAT+ | Jazz Pharmaceuticals to acquire Chimerix and its experimental brain cancer drug The drug, called dordaviprone, has been submitted to the FDA for accelerated approval, with a decision expected by Aug. 18. By Jason Mast STAT+ | FDA scolds drugmaker over promotion that touts 'misleading' comparison with generics The agency said an Edenbridge Pharmaceuticals' promotional panel falsely maintained there was greater patient adherence to its drug compared with generics. By Ed Silverman Adobe STAT+ | New radiopharmaceutical heading to the FDA after Phase 3 win The drug from ITM Isotope Technologies Munich SE has been developed as a treatment for gastroenteropancreatic neuroendocrine tumors. By Allison DeAngelis

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser